TLR4 and Alzheimer disease: Additionally, chronic intraperitoneal administration of CpG-ODN (TLR9 ligand) and monophosphoryl lipid A (MPL, TLR4 ligand) reduced Aβ plaques and NFTs, and restored cognitive deficits in AD mouse models (80, 88–91).